Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK5533524 in Advanced Solid Tumors
NCT07438782Phase 1Recruiting
- Sponsor
- GSK
- Start
- Mar 2026
- Primary completion
- Feb 2029
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 1, open-label trial of GSK5533524 in solid tumor (2 arms), sponsored by GSK. Primary endpoints: Dose Limiting Toxicities at 21 days, Adverse Events at 34 months and 1 more. Started Mar 2026; status: recruiting.
02
Drugs
GSK5533524
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07438782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07438782.